The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase
Phase 1
Started
2024-01-23
Last updated
2025-02-17
Condition(s) studied
Parkinson Disease
Investigational drug(s) / intervention(s)
Tenofovir Disoproxil Fumarate
Tenofovir Disoproxil Fumarate: take tenofovir disoproxil fumarate 300mg/d
Study summary
To evaluate the efficacy and safety of tenofovir disoproxil fumarate in the treatment of Parkinson's disease. The changes of motor symptoms and the occurrence of adverse reactions in early Parkinson's disease patients who took tenofovir disoproxil fumarate and did not take Tenofovir disoproxil fumarate at different time points were compared.
Eligibility
Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria:
* 1: Parkinson's disease: Hoehn Yahr= 1 to 2.5 2: MMSE score≥24
Exclusion Criteria:
* 1: essential tremor, stroke, epilepsy and other well-defined neurological disorders
2: Or have received deep brain stimulation and other brain surgery
3: Abnormal liver and kidney function
4: Infected with chronic hepatitis B or AIDS (HIV-1 infection)
5: Severe depression, schizophrenia, other psychiatric disorders or drug dependence
6: Other serious physical diseases such as heart, lung, liver, kidney disease, blood disease and malignant tumor
7: Pregnant or lactating women and seniors over 65 years of age
8: Allergy or other contraindications to the investigational drug
Primary outcome measure(s)
UPDRS III（Unified Parkinson's Disease Rating Scale part 3） — 1 month、3 month score：0-132，higher scores mean a worse outcome
Trial sites (1)
Facility
City
Region
Status
Guohua Zhao
Hangzhou
Zhejiang
Recruiting
More The Fourth Affiliated Hospital of Zhejiang University School of Medicine trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.